Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−4.30 EUR
−277.44 M EUR
372.57 M EUR
41.17 M
About Axsome Therapeutics, Inc.
Sector
Industry
CEO
Herriott Tabuteau
Website
Headquarters
New York
Founded
2012
ISIN
US05464T1043
FIGI
BBG01TNWGK98
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.
Related stocks
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Frequently Asked Questions
The current price of 1AXSM is 99.20 EUR — it has increased by 0.73% in the past 24 hours. Watch Axsome Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on MIL exchange Axsome Therapeutics, Inc. stocks are traded under the ticker 1AXSM.
1AXSM stock has fallen by −2.39% compared to the previous week, the month change is a 3.20% rise, over the last year Axsome Therapeutics, Inc. has showed a 7.50% increase.
We've gathered analysts' opinions on Axsome Therapeutics, Inc. future price: according to them, 1AXSM price has a max estimate of 171.19 EUR and a min estimate of 123.26 EUR. Watch 1AXSM chart and read a more detailed Axsome Therapeutics, Inc. stock forecast: see what analysts think of Axsome Therapeutics, Inc. and suggest that you do with its stocks.
1AXSM reached its all-time high on Sep 8, 2025 with the price of 108.40 EUR, and its all-time low was 86.05 EUR and was reached on Jul 28, 2025. View more price dynamics on 1AXSM chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
1AXSM stock is 1.08% volatile and has beta coefficient of 1.08. Track Axsome Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Axsome Therapeutics, Inc. there?
Today Axsome Therapeutics, Inc. has the market capitalization of 4.97 B, it has decreased by −5.81% over the last week.
Yes, you can track Axsome Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Axsome Therapeutics, Inc. is going to release the next earnings report on Nov 10, 2025. Keep track of upcoming events with our Earnings Calendar.
1AXSM earnings for the last quarter are −0.82 EUR per share, whereas the estimation was −0.90 EUR resulting in a 8.06% surprise. The estimated earnings for the next quarter are −0.70 EUR per share. See more details about Axsome Therapeutics, Inc. earnings.
Axsome Therapeutics, Inc. revenue for the last quarter amounts to 127.37 M EUR, despite the estimated figure of 117.16 M EUR. In the next quarter, revenue is expected to reach 138.35 M EUR.
1AXSM net income for the last quarter is −40.72 M EUR, while the quarter before that showed −54.92 M EUR of net income which accounts for 25.84% change. Track more Axsome Therapeutics, Inc. financial stats to get the full picture.
No, 1AXSM doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 23, 2025, the company has 683 employees. See our rating of the largest employees — is Axsome Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Axsome Therapeutics, Inc. EBITDA is −169.58 M EUR, and current EBITDA margin is −63.39%. See more stats in Axsome Therapeutics, Inc. financial statements.
Like other stocks, 1AXSM shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Axsome Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.